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Abstract
Zahilis Mazzochette
A STUDY OF ALBENDAZOLE AND ARTEMISININ DRUGS UNDER
ELECTROCHEMICAL OXIDATION
2017-2018
Amos Mugweru, Ph.D.
Master of Science in Pharmaceutical Sciences

This work is aimed to investigate the metabolic behavior of albendazole and
artemisinin. The electrochemical oxidation and reduction of these drugs were performed
on electrode materials to mimic their metabolism in vivo using cyclic voltammetry and
bulk electrolysis analysis. The oxidation of albendazole on gold electrode surface yielded
albendazole sulfoxide and albendazole sulfone which are the main metabolites of this
drug in vivo. Reduction of artemisinin on glassy carbon (GC) electrode surface yielded
dihydroartemisinin and deoxy artemisinin. The formation of these products was
monitored using liquid chromatography and mass spectrometry techniques. The redox
processes for both drugs were shown to be irreversible and diffusion controlled.
Bioactivation of artemisinin by hemoglobin was detected using a GC/carbon nanofibers
(CNFs)/Hb biosensor. The catalytic effect of hemoglobin lowered the reduction potential
of artemisinin by 475 mV. The apparent Michaelis-Menten constant (Km) was 0.093 mM
which shows excellent biological activity of the CNFs bound hemoglobin. Additionally,
the biosensor showed a linear relationship with increasing artemisinin concentration.
Therefore, it can be useful to determine concentration of this drug in solution and
matrices such as biological fluids.
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Chapter 1
An Introduction to Electrochemical Analysis of Pharmaceuticals
Electroanalysis of Pharmaceuticals
Application of electrochemical techniques to solve chemical problems started
with the invention of polarography in 1922 by Jaroslav Heyrovsky, and the polarograph,
one of the first automated analytical devices, by Heyrovsky and Shikata 1. Heyrovsky’s
invention had a significant impact on the advancement of electroanalysis. He was
awarded the Nobel Prize for chemistry in 1959 for this contribution 2. Electroanalysis
experienced its greatest advancement between the 1950s and 1970s with the development
of new methods and instrumentation as well as interest in improving the electrode
surfaces, which lead to the development of electrochemical sensors 1-2. Electrochemical
analysis has found applications in a wide variety of industries such as metal and
pharmaceutical industries, as well as in research, environmental, and occupational health
fields 3-4.
Electrochemical techniques have been utilized for the analysis of pharmaceuticals
since the 1960s 5. The interest in these techniques for drug analysis has increased
remarkably since then. The increase in popularity can be attributed to the development of
more sophisticated instrumentation and a better understanding of the techniques
themselves 6. Electrochemical techniques offer many advantages for the analysis of
pharmaceuticals including excellent sensitivity at very low concentration, rapid analysis,
small sample volumes, and easy sample preparation 5. They offer excellent methods for
concentration determination of drugs in pure solutions, dosage forms, and biological
fluids. Additionally, electrochemical methods are very useful to obtain information about
drugs’ pharmacokinetics, mechanism of drug action, and electron transfer parameters 7.
1

Electrochemical Techniques Often used for Drug Analysis
Potentiometry, coulometry, and voltammetry are popular electrochemical
techniques used for analysis of pharmaceuticals. Potentiometry methods measure the
potential of a solution, between the working and reference electrodes, due to an applied
controlled current. The difference in potential between the electrodes is used to determine
the concentration of the analyte or analytes in solution. Coulometric titrations involve the
generation of a chemical reactant at the electrode surface. Then, the generated reactant
undergoes a chemical reaction with the analyte. Control potential coulometry is often
referred to as bulk electrolysis. This technique will be described in more details later in
this chapter as it was used in drug oxidation. Voltammetric methods are based on the
application of a constant or varying potential at the surface of a working electrode and
measuring the resulting current. The potential or voltage applied at the working
electrode’s surface serves as the driving force to carry out reduction or oxidation
reactions 8. In voltammetry, the applied potential is the controlled parameter, and it can
be adjusted according to the reductive or oxidative properties of the drug species being
analyzed. Two different waveforms can be obtained using voltammetry a time-voltage,
and a current-voltage plot. A potential versus time waveform is obtained when a varying
voltage is applied over a period of time. The second plot is obtained by applying a
potential and measuring the current produced. The resulting curve is called a
voltammogram from which information about the electrochemical properties of the
species being analyzed can be obtained 8. Voltammetry is very popular for the analysis of
drugs and pharmaceuticals 4. The choice of voltammetric method depends on the type of
analyte and parameters to be determined. Table 1 shows different types of voltammetric
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methods that have been used for the analysis of pharmaceuticals. In this work, cyclic
voltammetry, amperometry, and bulk electrolysis are the electroanalytical methods used
to study the redox behavior of albendazole and artemisinin. Therefore, a detailed
discussion of these methods is offered.

3

Table 1
Voltammetric methods used for quantification, mode of action, and kinetic studies of
pharmaceuticals.

Method

Drug

Type of Study

References

Cephalexin,
Daunomycin, Dopamine
Acetaminophen
Chloroquine

Quantification,
Mechanism of action,
Electrochemical
behavior, Kinetics

Nitrofurantoin,
Riboflavin, Doxazosin
Nandrolone
Ceftazidime

Quantification,
Electrochemical
behavior

14-19

Anodic Stripping
Voltammetry (ASV)

Dopamine, Doxazosin

Quantification

14, 16

Cathodic Striping
Voltammetry (CSV)

Chlordiazepoxide
Norﬂoxacine, Enoxacine

Adsorptive Stripping
Square Wave
Voltammetry
(AdSSWV)

Carvedilol, Levoﬂoxacin
Metoclopramide

Quantification,
Electrochemical
behavior
Electrochemical
behavior,
quantification

Cyclic Voltammetry
(CV)

Square wave
Voltammetry (SWV)

9-13

20-21

22-24

15, 17

Differential Pulse
Voltammetry (DPV)

Electrochemical
Nandrolone, Bergenin,
behavior,
Trimebutine, Ceftazidime quantification

Differential Pulse
Polarography (DPP)

Artemether, Ciclopirox
olamine

Quantification

27-28

Electrochemical
behavior,
quantification

29-31

Quantification

32

Amperometry

Isoniazid, Ascorbic acid
Sodium metabisulfite

Adsorptive Striping
Voltammetry (ASV)

Ofloxacin,
Fluoroquinolones
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Cyclic voltammetry. Cyclic voltammetry (CV) is a versatile analytical technique
widely used in many areas of electroanalytical chemistry 4. CV is especially popular for
the analysis of drugs and pharmaceutical. In fact, it is among the first experiments carried
out on drugs that are electro-active 33. Cyclic voltammetry can be used to determine
concentration of analytes, and it is especially useful for the study of redox reactions and
homogeneous chemical reactions coupled to electron transfer processes 34. During a CV
experiment, the potential of the working electrode is ramped linearly versus time. The
voltage applied to the working electrode is increased from an initial value Einitial to a
predetermined limit, Elimit (the switching potential). At this point, the direction of the
scan is reversed completing one full cycle. The scanning can be stopped at this point, or a
series of cycles between Einitial and Elimit can be performed. Repeated scanning is very
useful to probe the stability of modified working electrodes 35. Furthermore, changes that
appear on repetitive scans can reveal information about reaction mechanisms 8.
Amperometry. Amperometry is classified as a voltammetric method. In
amperometry, a constant reducing, or oxidizing potential is applied, and the resulting
steady-state current is usually measured as a function of time 36. The magnitude of the
resulting current correlates with the concentration of the oxidized or reduced analyte.
Therefore, this technique is reliable and efficient to determine the concentration of one or
numerous electroactive substances in solution by selectively choosing the magnitude of
the applied potential and electrode material 36. Amperometry is also widely used for the
analysis of electrochemical sensors and biosensors 36.
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Bulk electrolysis. Control potential coulometry is referred to as bulk electrolysis.
With this technique, a constant potential is applied to oxidize or reduce the substance of
interest completely. A large working electrode with a surface area about one hundred
times larger than a standard electrode is used to speed up the electrochemical conversion.
The experiments are carried out under stirring conditions to aid transport of electroactive
material to the electrode surface. “In controlled potential coulometry, the potential of the
working electrode is maintained at a constant level such that the analyte conducts charge
across the electrode-solution interface. The charge required to convert the analyte to its
reaction products is then determined by integrating the current-versus-time curve during
the electrolysis” 37. The amount of charge measured during the experiment is used to
determine the concentration of analyte in solution. Therefore, controlled potential
coulometry is a very valuable technique for quantitative analysis 38. This technique can be
used for synthetic purposes as long as the product is neutral and can be isolated from the
electrolyte solution. If the products cannot be isolated, then analytical techniques such as
UV-Vis, NMR, HPLC, and mass spectrometry (MS) can be utilized to analyze them in
solution 38. In this work, bulk electrolysis was used to completely electrolyzed samples of
albendazole and artemisinin. The electrolysis products were analyzed using HPLC-MS.
The Electrochemical Cell
Most electrochemical analysis of pharmaceuticals takes place in a three-electrode
electrochemical cell which consists of a working electrode, an auxiliary or counter
electrode, a reference electrode, and a supporting electrolyte. Redox reactions take place
on the surface of the working electrode. The choice of working electrode depends on the
nature of the analyte and the type of analysis to be performed. For example, cyclic
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voltammetry is performed using working electrodes with a small surface area such as a
standard gold, glassy carbon or platinum electrode (Figure 1a) while bulk electrolysis can
be performed efficiently and rapidly by using a working electrode with a large surface
area (Figure 1b). Standard working electrodes are mostly covered with insulating material
just leaving a carefully controlled circular area exposed (about 1mm wide) where
the reaction takes place. The auxiliary electrode is usually a platinum electrode, and it is
needed to complete the circuit along with the working electrode. The reference electrode
is used to measure the applied potential and does not pass any current. A supportive
electrolyte is used to avoid migration of the species of interest through the solution. In
some experiments, the supportive electrolyte can be used as a solvent.

7

a)

b)

Figure 1. Electrochemical cells: a) a typical voltammetry cell. b) Bulk electrolysis cell,
featuring a large carbon working electrode.
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Research Objective
Understanding the electrochemical behavior of pharmacologically active
molecules is of high importance since metabolic pathways of these molecules undergo
redox transformations 39. Due to the similarities between biological and electrochemical
reactions, it can be assumed that redox mechanisms taking place at the electrode surface
and inside the body happen through similar processes. Therefore, the redox properties of
drug molecules can give us insight into their metabolic fate and pharmacological activity
in vivo 33. This study is aimed to use chromatographic and electroanalytical techniques to
elucidate mechanistic parameters from the redox reactions of albendazole and
artemisinin. Both albendazole and artemisinin have been reported as potential anticancer
agents 40-41. A clear understanding of the electron transfer processes of these drugs is
fundamental to better understand their anticancer properties and for the development of
more potent analogs.
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Chapter 2
Electrochemical Oxidation of Albendazole
Introduction
Albendazole (ABZ) is a broad spectrum benzimidazole carbamate used for the treatment
of helminths and diseases such as neurocysticercosis, strongyloidiasis, and
microsporidiosis caused by such parasites 42-43. Albendazole has been in use for about 40
years in humans and animals with few side effects among them mild gastrointestinal
discomfort, dizziness, and rash 44. ABZ is a prodrug which is oxidized by liver enzymes
and transformed into albendazole sulphoxide (ASOX) its pharmacologically active
metabolite. Albendazole sulphoxide is further oxidized into albendazole sulphone
(ASON) an inactive metabolite 44-45 (Figure 2). Albendazole works by selectively binding
to parasites’ ß-tubulin preventing the formation of microtubules and stopping cell
division. It also impairs glucose uptake leading to energy depletion and parasite death 4647

. Albendazole’s solubility in aqueous solution is very poor due to the nature of its

molecular structure hence high concentration of this drug is administered to improve
absorption and achieve therapeutic levels 48-49. Pharmacokinetics of albendazole have
been studied in both human and animals. The rate of absorption of albendazole was found
to be erratic and varies greatly between individuals and animal species 49-50. There is
continued interest in the study of albendazole’s properties and metabolism. In fact, there
has been extensive research in developing attractive and fast methods for studying ABZ
and its metabolites. Several reported analytical techniques for the analysis of albendazole
include ultrahigh performance LC coupled with a mass spectroscopy detector, highperformance liquid chromatographic (HPLC) 51-53, solid phase extraction coupled with

10

HPLC, and electrochemical studies 54-55. In this chapter, the electrochemical oxidation of
albendazole is carried out to elucidate significant kinetic parameters helpful for further
understanding of its metabolic fate.

Figure 2. Albendazole and its metabolites: Albendazole sulphoxide and albendazole
sulphone 39.
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Experimental Methods
Chemicals. Albendazole was purchased from Sigma Aldrich. Tetrabutyl
ammonium bromide (TBAB) was purchased from WWR (West Chester, PA). A (7.55 ×
10-3 M) albendazole solution in acetonitrile containing (0.05M) TBAB as the supporting
electrolyte was used for this study. All analytical reagents were used as received. DI
water was used for all other applications. All chemicals were of analytical grade or HPLC
grade.
Electrochemical apparatus. Cyclic voltammetry (CV) and amperometric
studies were carried out with a computer controlled electrochemical workstation (CHI
660c, USA) with an ohmic drop (IR) 98% compensated. A three-electrode
electrochemical cell with a glassy carbon working electrode, a platinum wire as a counter
electrode, and a Ag/AgCl as the reference electrode were used for all electrochemical
experiments. The Ag/AgCl reference electrode was equipped with a glass tip, separated
from the sample solution compartment by a salt-bridge containing KCl and terminating in
a medium porosity glass frit. Cell resistance, IR, as measured by the CH Instruments, was
98% compensated in all voltammetric experiments. All work was done at the ambient
temperature of the laboratory (23℃).
Electrode surface preparation procedure. The glassy carbon working electrode
(0.07 cm2) and the platinum wire counter electrode were obtained from Bioanalytical
Systems Inc. (West Lafayette, IN). Glassy carbon electrodes require polishing in alumina
(0.1 µm particle sizes) and rinsing thoroughly in pure water and finally ultra-sonicated in
the same media before use. Prior to this study, glassy carbon electrodes were initially
polished on one μm diamond polishing paste then ultrasonicated in ethanol and distilled
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water successively for 1 minute, followed by rinsing in pure water and then dried in air.
This step was then followed by alumina polishing and thorough rinsing, as indicated
above.
Chromatographic procedure. The HPLC-UV analysis was carried out using an
Agilent 1100 series HPLC unit. The UV detector was set at 254 nm wavelength.
Separations were carried on a ZORBAX XDB-CN column (4.6 mm × 150 mm long and
five μm particle size, Agilent Technologies). A Zorbax CN guard column (4.6 mm
cartridge, Agilent Technologies) was used to preserve the analytical column. The mobile
phase consisted of acetonitrile methanol and DI water (59:27:14). The chromatographic
run was performed at a flow rate of 1 mL/min.
Mass spectrometry procedure. The mass spectrometer was a Micromass Quattro
micro unit. It was set to ESI in positive ion mode. The settings of the mass spectrometer
were as follows: the desolvation gas (N2) and flow were operated at 500 ℃ and 5 L/min,
respectively. The corona was operated at 2 μA while the cone voltage was set at 25 V.
The extractor lens was at 5 V while the RF lens was at 0.2 V. The mass spectrometry
collision gas was an N2 of high purity (>99.9995).
Results and Discussion
Voltammetric oxidation of albendazole. The electrochemical oxidation of ABZ
was studied on a glassy carbon electrode surface using cyclic voltammetry. The cyclic
voltammogram of 7.55 × 10-3 M albendazole solution in acetonitrile was recorded at a
potential window from 0 V to 2.0 V versus Ag/AgCl reference electrode. The
voltammogram shows two broad anodic peaks (Figure 3).
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Figure 3. Cyclic voltammogram of (7.55 × 10-3 M) ABZ in acetonitrile containing 0.05M
TBAB solution. CV was performed using a glassy carbon electrode at 30 mV/s scan rate.

The first peak was at about 1.2 V versus Ag/AgCl reference electrode and the second
peak occurred at about 1.6 V. During the reverse scan, no reduction peak corresponding
to the anodic response was observed which indicates that the oxidation of albendazole is
an irreversible process 39, 56. In a reversible process, a cathodic or reduction peak of about
the same magnitude of the anodic peak is formed during the reverse scan and vice versa.
The reversibility or irreversibility of an electrochemical reaction provides significant
information about the rate at which the electron transfer occurs between the working
electrode and the redox species in solution. Reversible reactions occur quickly without
significant thermodynamic barriers. If the electron transfer is not fast enough and the
electrochemically generated species is not stable, the unstable species undergoes a
chemical reaction rendering the system irreversible 56. Cyclic voltammetry is an effective
technique for detecting the formation of reaction intermediates as in the case of ABZ.
14

Oxidation of ABZ at the electrode surface leads to the formation of albendazole sulfoxide
which undergoes further oxidation and transformed into albendazole sulfone 45. The first
and second peak waves in figure 3 were later confirmed using LC-MS to be due to the
formation of albendazole sulfoxide and albendazole sulfone respectively. The measured
peak current of the first peak wave was found to increase with the scan rate while the
second peak also increased accordingly but disappeared at scan rates higher than 100
mV/S. The disappearance of the second peak indicates that ASON did not form at scan
rates higher than 100 mV/S.
The scan rate analysis indicates that the oxidation of albendazole is controlled by
diffusion. Diffusion of analyte towards the electrode occurs when there is a concentration
difference between the electrode surface and the bulk solution. As species are reduced or
oxidized at the electrode surface, a concentration gradient is formed. Molecules move
from areas of greater concentration to areas of lesser concentration 37 at a rate dictated by
the concentration gradient. A plot of peak current versus the square root of scan rate (v1/2)
produced a linear relationship (Figure 4a), suggesting a diffusion-controlled electrode
process according to the accepted theory 57-58. Increasing the scan rates also increases the
potential at the electrode surface. As a result, the concentration of analyte at the electrode
surface becomes smaller, and diffusion towards the electrode surface increases 37. The
peak potential (Ep) of the anodic peaks were also dependent on the scan rate. Ep shifted to
more positive potentials on increasing the scan rate. A linear relationship between the
peak potential and log (scan rate) was obtained (Figure 4b). Such linearity confirms the
irreversible nature of the electro-oxidation of albendazole 59.
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Figure 4. Albendazole (7.55 × 10-3 M) in acetonitrile showing peak currents and peak
potentials: (a) Peak currents versus square root of scan rate; (b) Peak potentials with log
of scan rate for peak wave at 1.2 V versus Ag/AgCl electrode.

 i 
 at a scan rate of 100 mV/s; (b) Measured
Figure 5. Applied potential vs. log 
 il  i 
current (Ln (ip) versus (E-E1/2) at a scan rate of 100 mV/s for (7.55 x 10-3 M) albendazole
in acetonitrile containing 0.05M TBAB at a glassy carbon electrode.
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Kinetic parameters for albendazole’s oxidation were estimated using experimental
data obtained from figure 5 above together with equations 1, 2, and 3.

E  E1/ 2 

 i 
RT

log 
nF  il  i 

i p  0.227 nFAC 0 K h e

na F
RT

Equation 1

E  E1/ 2 

Ln i p   Ln 0.227 nFAC0 K h  

na F
RT

Equation 2

E  E1/ 2 

Equation 3

Where i is the current at any measured potential and il is the limiting current, α is the
coefficient of electron transfer, n is the number of electrons transferred, E1/2 is the midpoint potential, E is the applied potential, T is the temperature in Kelvin (298), R is the
gas law constant (8.314), F (Faraday constant = 96480), kh is the heterogeneous rate
constant, A is the area of the electrode surface, and C0 the initial analyte concentration.

 i 
 (Figure 5a) gives a straight line which slope and yA plot of E versus log 
 il  i 
intercept relate to the charge transfer characteristics. The y-intercept corresponds to the
value of E1/2 which according to Figure 5a was found to be 0.91V versus Ag/AgCl. The
plot of Ln ip versus (E-E1/2) (Figure 5b) also gave a straight line whose y-intercept and
slope provide information to calculate the heterogeneous rate constant and electron
transfer coefficient using equation 5. For an irreversible system, α is assumed to be 0.5 60.
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Hence the number of electrons transferred in the electro-oxidation of ABZ to ASOX was
calculated as 1.3 1. The value of Kh was calculated to be about 1.39 × 104 S-1 cm2. The
average current density at 100 mV/s was about 214 µA/ cm2 which also supports the
diffusion-controlled mass transport of albendazole towards the electrode surface.
Figure 6a shows the plot of peak current versus scan rates for the second peak
wave obtained during the electro-oxidation of ABZ. This peak was only observed at scan
rate lower than 100 mV/s and potentials higher than 1.5 V versus Ag/AgCl electrode. A
linear relationship between peak current and the square root of scan rates was obtained
for the second peaks as well (Figure 6b). Like the conversion of ABZ to ASOX, this
indicates that the electron transfer reaction for the conversion of ASOX to AZON is
diffusion controlled.

Figure 6. Variation of peak current for (7.55 x 10-3 M) albendazole for second peak
wave: a) with scan rate b) with square root of scan rate at glassy carbon electrode.
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A plot of Ep versus scan rate was obtained under the same scan rate values (Figure
7a). The relationship between the peak potential and log ν was linear (Figure 7b) with a
correlation coefficient of 0.990. Such behavior reveals the irreversible nature of the
electrochemical oxidation of ASOX to ASON.

Figure 7. Variation of peak potential for (7.55 x 10-3 M) albendazole for second peak
wave: a) with scan rate b) at glassy carbon electrode.

Bulk electrolysis analysis. The electrolysis of albendazole (7.5 x 10-3 M) in a
59:27:14 mixture of acetonitrile, methanol, and deionized water solution was carried out
using a glassy carbon electrode. The purpose of bulk electrolysis is to completely oxidize
or reduce the analyte in solution. During bulk electrolysis, the solution is constantly
stirred to maintain a continuous flow of fresh solution in the vicinity of the electrode
surface. This type of mass transport is called forced convection, and it is the simplest way
of transferring the electroactive species to the electrode surface 37. The electro-oxidation
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of albendazole was investigated as a function of time at two different potentials (1.5 V
and 1.7 V). First, the electrode potential was fixed at 1.5 V versus Ag/AgCl for six hours.
1 ml of the electrolyzed solution was drawn out every hour using a syringe and filtered
using a 0.45 nm filter. The same procedure was carried out at 1.7 V. The solutions were
analyzed using HPLC and mass spectrometry.
Chromatographic analysis. Figure 8a shows the chromatograms of ABZ before
and after 1-5 hours of electrolysis. The peaks at about 1.9 minutes correspond to
unreacted ABZ molecules with the highest peak corresponding to albendazole solution
before electrolysis. After one hour of electrolysis, a chromatographic peak appeared at
about 1.7 minutes and another smaller peak at about 1.5 minutes. These peaks can be
attributed to the oxidation products of albendazole. The peak at 1.7 minutes increased
remarkably as the electrolysis continued while the smaller peak was saturated after three
hours of electrolysis. The peak due to albendazole (peak at 1.9 min.) decreased as the
electrolysis proceeded indicating its consumption as the products were formed. Figure 8b
illustrates the reactant and products profile as a function of electrolysis time.
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a)

b)

Figure 8. Chromatographic analysis of electrolyzed solution of ABZ: a) sampled at
different times using UV detector at 254 nm and electrolyzed at 1.5 V versus Ag/AgCl
electrode and b) reactant and products profile measured as a function of time using the
chromatographic results obtained from the electrolysis of albendazole.
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Increasing the voltage of electrolysis from 1.5 V to 1.7 V resulted in the formation
of another chromatographic peak at 2.5 minutes and disappearance of the peak at 1.5
minutes (Figure 9). This new peak can be correlated to the anodic peak at about 1.6 V
obtained on the CV of albendazole (Figure 3). Both peaks are likely due to the formation
of albendazole sulfone.

Figure 9. Chromatographic analysis of ABZ solution electrolyzed at 1.7 V versus
Ag/AgCl electrode, sampled at different times using UV detector at 254 nm.

Further characterization of the electro-oxidation products of albendazole was
carried out with an LC-MS Instrument using the same column and mobile phase flow
rates as above. Figure 10 shows a mass spectrum of the initial ABZ peak obtained at 1.9
minutes. The initial drug, labeled A in the figure has well-known fragments with m/z of
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the molecular ion at 266, other fragments with m/z 234, 191, correspond to structures B
and C. Wu et al. 55 also observed these fragments during MS analysis of albendazole.

Figure 10. Mass spectrum of albendazole before electrolysis. Chromatographic peak at
1.9 minutes.

Figure 11 shows the mass spectra for the chromatographic peak at 1.7 minutes.
This peak is likely due to the formation of albendazole sulfoxide since it experienced
steady increase with time of electrolysis. The fragment with m/z 282 (D in figure 11) can
be attributed to the molecular ion of ASOX. Fragments with m/z of 207 and 239 are
given as E and F.
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Figure 11. Mass spectrum of albendazole after electrolysis. Chromatographic peak at 1.7
minutes.

Figure 12. Mass spectrum of albendazole after 4 hours of electrolysis. Chromatographic
peak at 2.5 minutes.
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Figure 12 shows the mass spectra of the chromatographic peak at 2.5 minutes.
This peak is thought to represent the formation of albendazole sulphone on the electrode
surface. The molecular ion peak of albendazole sulphone is likely to be m/z 297. Other
fragments obtained such as m/z of 159, 206, and 108.95 could not be accounted for.
Conclusion
The electrochemical oxidation of albendazole on glassy carbon electrode surface
followed and ECE (multiple electron transfer with intervening chemical reaction)
mechanism. Two electrons are transferred during the electrode process although not in a
concerted fashion. The first step involves oxidation of albendazole followed by a
chemical reaction and formation of albendazole sulfoxide. In the second step, ASOX is
oxidized with subsequent formation of albendazole sulfone. The electrode reaction was
therefore irreversible and limited by diffusion-controlled mass transfer. αn was calculated
to be 0.652 and Kh was approximately 1.39 × 104 S-1 cm2. Bulk electrolysis followed by
HPLC analysis confirmed the generation of two electrolysis products. The products
eluded at 1.7 and 2.5 minutes (Figures 14) can be attributed to the formation of
albendazole sulfoxide and albendazole sulfone respectively. Mass spectra of the
electrolyzed solution of albendazole reveal peaks at m/z 282 and m/z 297 that can be
representative of the molecular ions of ASOX and ASON. These results further support
the formation of these products during electrolysis.
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Chapter 3
Electrochemical Reduction of Albendazole on Gold Electrode Surface
Introduction
The efficacy of albendazole has been well established for the treatment of
helminths and related diseases 43 in spite of its low aqueous solubility. Albendazole is
administered orally and in high dosages in order to achieve therapeutic concentrations 61.
There has been increased interest in the study of albendazole’s aqueous solubility 62-65 to
improve the formulation process for oral administration as well as for development of
systemic formulations. Various studies have shown that albendazole has promising
anticancer properties against various types of cancer tumors, i.e., colorectal, pancreatic,
ovarian, breast, and prostate cancer 66-67. However ever, because of its poor solubility,
albendazole cannot be administered intravenously. None or very little of this drug reaches
the systemic circulation when administered orally due to erratic absorption and extensive
first-pass metabolism 64. Therefore, continued research on albendazole is essential.
Voltammetric techniques have been shown very effective for kinetics and metabolic
studies of pharmaceutical compounds. Chapter 2 of this work focuses on the
electrochemical oxidative behavior of albendazole. In this chapter, its reductive behavior
on gold electrode surface is investigated.
Experimental Methods
Chemicals. Acetonitrile, methanol, Tetrabutylammonium bromide (TBAB) were
purchased from WWR (West Chester, PA). Albendazole was purchased from Sigma
Aldrich. The albendazole solution was prepared in a 1:1 ratio of acetonitrile/methanol as
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the solvent containing (TBAB). The TBAB was used as the supporting electrolyte. All
other chemicals were HPLC grade.
Electrochemical apparatus. Electrochemistry was carried out with a computer
controlled electrochemical workstation (CHI 660c, USA) with 99%ohmic drop or IR
compensation. A gold electrode was used as the working electrode, a platinum wire as the
counter electrode, and a Ag/AgCl reference electrode were used for all electrochemical
experiments. The Ag/AgCl was equipped with a glass tip, separated from the sample
solution compartment by a salt-bridge containing KCl and terminating in a medium
porosity glass frit. All electrochemical measurements were carried out under ambient
conditions.
Electrode surface preparation. The gold working electrode (0.01 cm2) and the
platinum wire counter electrodes were obtained from Bioanalytical Systems Inc. (West
Lafayette, IN). The gold electrode was polished using alumina (0.1 mm particle size) and
rinsed thoroughly in pure water and finally ultra-sonicated in methanol for 1minute,
followed by rinsing in pure water and then dried in air.
Bulk electrolysis procedure. The bulk electrolysis reduction of albendazole was
carried out in tetrabutylammonium bromide-acetonitrile solution under stirring conditions
for 7 hours. The potential of the reaction was fixed at 1.5 V versus Ag/ AgCl. 100 mL
aliquots of the reaction mixture were withdrawn every hour. The solution reaction
mixtures were diluted with mobile phase, filtered and analyzed using chromatographic
techniques.
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HPLC procedure. The chromatographic analysis was carried out using an
Agilent 1100 series HPLC unit. The detector was a UV-Visible with the wavelength set
at 254 nm. Separations were carried out at room temperature on a C-18 column
ZORBAX 300SB (4.6X150 mm long and with 3.5 mm particle size, Agilent
Technologies). The mobile phase consisted of acetonitrile, methanol and de-ionized water
(59:27:14). The chromatographic run was performed under isocratic conditions at the
flow rate of 1mL/min.
Mass spectrometry procedure. The mass spectrometry analysis was performed
using a Micromass Quattro micro API Mass Spectrometer. The MS was set to ESI in
positive ion mode. The settings of the mass spectrometer were as follows: the desolvation gas (N2) and flow were operated at 1988Cand 249 L/hour respectively. The
corona was operated at 2 mA, while the cone voltage was set at 60 V. The extractor lens
was at 3Vwhile the RF lens was set at 0.0 V. The mass spectrometry collision gas was an
N2 of high purity (>99.9995).
Results and Discussion
Voltammetric reduction of albendazole. Reduction of albendazole was
investigated on gold electrode surface using cyclic voltammetry. A 0.05 M TBAB
solution was used as the supporting electrolyte to avoid electrolytic migration of ABZ
molecules as the potential is applied. The reduction was carried out at a potential window
of 1.0 V to -1.6 V versus Ag/AgCl electrode. The recorded cyclic voltammogram shows
three well-defined reduction peaks (Figure 13). The first peak was at about -1.0 V versus
Ag/AgCl reference electrode, the second peak occurred at around -0.6 V, and the third
peak was registered at +0.1 V. During the reverse scan, no oxidation peaks corresponding
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to the reduction peaks were observed. This suggests that the reduction of albendazole is
irreversible. As previously mentioned, in a reversible process, the reverse scan forms a
cathodic or anodic peak of about the same magnitude of the peak formed during the
forward scan. As the scan rate was increased, the peak current shifted to more negative
potentials which also indicates the irreversibility of the system.

Figure 13. Scan rate dependence of albendazole. (1.8 x 10-3 M) ABZ dissolved in
acetonitrile containing 0.05 M TBAB at scan rates taken from 30-180 mV/s.

The resulting peak current for the three peak waves was found to increase linearly
as the scan rate was increased. This linear relationship can be observed in Figure 14
obtained by plotting the peak current versus the scan rate from 30 mVs-1 to 180 mVs-1 for
the three peaks. However, at higher scan rates (10-1000 mV/s), the peak current is no
longer linear with increasing scan rate but preserves its linear relationship with the square
root of the scan rate as it can be observed in figure 15 (peak centered at around -1.0 V).
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Figure 14. Peak current as a function of scan rate. (1.8 x 10-3 M) ABZ in acetonitrile
containing 0.05 M TBAB for the three peaks in figure 17.

Figure 15. Peak current of ABZ at scan rates of 10-1000 mV/s. (1.8 x 10-3 M) ABZ in
acetonitrile containing 0.05 M TBAB for the third peak centered around -1.0 V versus
Ag/AgCl: A) peak current versus scan rate B) peak current versus square root of scan
rate.
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A linear relationship between peak current and square root of scan rate (V1/2)
suggests a diffusion-controlled reduction process on the electrode surface as it is
generally accepted 68-69. During cyclic voltammetry studies, the current produced due to
an electrochemical reaction can be visually observed by studying the obtained cyclic
voltammogram. The peak current represents the current that diffuses to the electrode
surface during the electrochemical reaction and can be described by equation 4 below.

i p  0.229 10 5 nn 

1/ 2

AC  D1/ 2V 1/ 2

Equation 4

Where A is the electrochemically active surface area, D is the diffusion coefficient, C* is
the bulk concentration of the analyte, n represents the number of electrons transferred
during the reaction, α is the coefficient of electron transfer, and V1/2 is the square root of
the scan rate. The average diffusion coefficient for the electro-reduction of ABZ was
estimated to be 0.143 x 10-8 cm2/s using the slope of the lines of Figure 16 and equation
4.
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Figure 16. Peak current as a function of square root of scan rate. (1.8 x 10-3 M) ABZ in
acetonitrile containing 0.05 M TBAB for the three peaks in figure 13.

The value of n can be calculated from the slope of the line in Figure 17 (Ep vs.
log v). For an irreversible electrode process, the linear relationship between peak
potential and logarithm of the scan rate can be expressed by equation 5 59, 70.
.
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Figure 17. Peak potentials (EP) of (1.8 x 10-3 M) ABZ in acetonitrile containing 0.05 M
TBAB on gold electrode for the second peak wave. A represents the plot of EP versus
scan rate, and B represents EP versus log scan rate.

RTK  2.303RT
 2.303RT 
E p  E0  
log

log v

nF
nF
 nF 

Equation 5

Where Ep represents the peak potential, E0 is the formal potential, T is the temperature in
Kelvin (298), R is the gas law constant (8.314), F (Faraday constant = 96480), k⁰ is the
standard heterogeneous rate constant,  is the transfer coefficient, n is the number of
electrons transferred, and v represents the scan rate. The slope was -0.117 and n was
found to be 0.513. For the third peak n was calculated similarly and was found to be
0.496.
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Bulk electrolysis analysis. The three reduction waveforms observed on the cyclic
voltammograms (Figure 13), indicate that three different species were formed at the gold
electrode surface during the CV analysis of ABZ. To investigate the species formed, bulk
electrolysis was carried out to completely electrolyzed the solution and obtain
quantifiable amounts of the products. The electrolysis was carried over a period of seven
hours using a gold working electrode, and the potential was set at -1.5 V versus Ag/AgCl.
7.5 x 10-3 M ABZ solution was constantly stirred during electrolysis to maintain a
continuous flow of fresh solution to the electrode surface. This type of mass transport
technique is a simple way of transferring the analyte molecules to the electrode surface
and achieve complete electrolysis. Complete electrolysis of the ABZ molecules is
important to recover the necessary amount of product for further characterization. The
reduction products were monitored every hour using HPLC-MS analysis.
HPLC-MS analysis of reduction products. In order to characterize the
reduction products of albendazole, 100 μL aliquots of the electrolyzed solution were
drawn out every hour and diluted to 1mL before filtration using a 0.45 nm filter. Liquid
chromatography analysis revealed three major peaks with retention times at 3.4, 3.9 and
4.4 minutes. The peak at 3.9 minutes corresponds to unreacted ABZ. The peaks at 3.4 and
4.4 minutes corresponds to the reduction products of ABZ. The chromatogram (Figure
18) shows a clear increase in the product eluding at 3.4 minutes (peak 1) as the time of
the electrolysis increases. The product eluting at 4.4 minutes (peak 3) appeared after one
hour of electrolysis, and its concentration seems to be higher than that of the product
eluding at 3.4 minutes. Peak 3 increased consistently with the time of electrolysis from
1hour to 4 hours. However, after seven hours of electrolysis peak 3 decreased noticeably,
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and peak 1 experienced higher increase. This could indicate that the product eluding at
3.9 minutes is reacting to form more of the product eluding at 3.4 minutes. The
concentration of ABZ remained higher than any of the products formed at any time
during the electrolysis indicating that only a small percentage of the drug was being
reduced during the seven hours process.

Figure 18. Chromatographic analysis of albendazole after electrolysis at – 1.5 V for
seven hours.

The products formed during the bulk electrolysis of albendazole were further
analyzed using mass spectrometry in an attempt to identify them. The pure ABZ eluted at
3.9 minutes (peak 2) on the HPLC chromatogram (Figure 18). The mass spectrum of
peak 2 includes M/Z of 265, 234, and 307 (Figure 19). The mass spectra of the products
eluted at 3.4 minutes (Figure 20) shows peaks with M/Z of 240 281, and 284. The
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presence of peaks with higher M/Z than the initial molecule could indicate initial
oxidation of albendazole to ASOX. However, further analysis is needed in order to
identify the products formed during the electrochemical reduction of albendazole.

Figure 19. Mass spectrometry of albendazole after electrolysis at – 1.5 V for peak
eluding at 3.9 minutes.
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Figure 20. Mass spectrometry of albendazole after electrolysis at – 1.5 V for peak
eluding at 4.35 minutes.

Conclusion
The cyclic voltammogram obtained during the electrochemical reduction of ABZ
on gold electrode surface, suggests the formation of three reduction products. By
examining the CV at different scan rates, it can be asserted that the electrode process was
irreversible and limited by diffusion-controlled mass transport. The reactions on the
electrode surface followed and ECE mechanism which allowed the formation of the
products by an electron transfer reaction followed by a chemical step. αn was calculated
to be 0.513 and 0.496 for the second and third peak respectively. The reduction products
of ABZ could not be accurately identified using the obtained HPLC-MS results. Further
work should include isolation of ABZ reduction products for characterization using
techniques such as IR and NMR.
37

Chapter 4
Electrochemical Reduction of Artemisinin
Introduction
Artemisinin (Art) and its derivatives (i.e., dihydroartemisinin and artemether)
constitute the front-line treatment for malaria worldwide. Art is isolated from the Chinese
plant Artemisia Annua. The use of Artemisia Annua in traditional Chinese medicine
dates to 168 B.C. for the treatment of fever, helminth infections, and malaria 71. The
isolation and structure elucidation of artemisinin was published in 1972 by the Chinese
scientist Youyou Tu who was partially awarded the 2015 Nobel Prize for medicine for
this discovery 72. Artemisinin is an enantiomerically pure sesquiterpene lactone. Its
pharmacophore consists of a 1, 2, 4 trioxane ring containing an endoperoxide bridge
(Figure 21). Art is very effective against Plasmodium falciparum, the malaria-causing
parasite. Unfortunately, studies have reported that plasmodium falciparum is becoming
resistant to artemisinin. Currently, an artemisinin-based combination therapy (ACT) is
being used to slow down the parasite resistance mechanism. Artemisinin is also being
investigated as a potential anti-cancer agent. Studies have found that it is highly active
against different cancer cell lines such as leukemia, colon, and breast cancer 73. In this
study, the electrochemical reduction behavior of artemisinin was investigated using cyclic
voltammetry and bulk electrolysis. The reduction products were analyzed using HPLC,
and HPLC-MS.
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Figure 21. Structure of artemisinin, a sesquiterpene lactone-containing a 1, 2, 4-trioxane
ring pharmacophore.

Experimental Methods
Chemicals. Artemisinin was purchased from Tokyo Chemical Industry Co., TLD.
Tetrabutylammonium bromide (TBAB) was purchased from WWR (West Chester, PA).
The artemisinin solutions (0.03 M) were prepared using acetonitrile as the solvent and
0.05 M TBAB being the supporting electrolyte. A 50:20:30 mixture of Acetonitrile,
methanol, and deionized water were used for the mobile phase.
Bulk electrolysis/cyclic voltammetry procedures. The electrochemical analysis
was carried out with a computer controlled electrochemical workstation (CHI 660c,
USA) with 98% ohmic drop (IR) compensation. A bulk electrolysis electrochemical cell
was used for all electrochemical experiments. A gold electrode was used as working
electrode for cyclic voltammetry analysis. Before use, the gold electrode was polished
using 1 µm diamond polishing paste then ultra-sonicated in ethanol and distilled water
successively for 1 min followed by rinsing with water. The electrolysis of artemisinin
was carried out in ammonium bromide-acetonitrile solution under stirring conditions for
3hours. The potential of the reaction was fixed at 1.5 V versus Ag/ AgCl. 0.5 mL aliquots
of the reaction mixture were withdrawn every hour then filtered and analyzed using
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chromatographic and mass spectrometry techniques. The solvents used were compatible
with the mobile phase.
HPLC procedure. The HPLC analysis of artemisinin reduction products was
carried out on a ZORBAX C-18 300SB column (4.6 x150 mm long and with 3.5 µm
particle size, Agilent Technologies). The mobile phase consisted of acetonitrile, methanol
and de-ionized water (50:25:25) respectively with 0.1% formic acid. The HPLC-UV
analysis was carried out using Agilent 1100 series HPLC unit equipped with an UVVisible detector with the wavelength set at 254 nm. The chromatographic run was
performed under isocratic conditions at the flow rate of 100 µL /min.
Mass spectrometry procedure. The mass spectrometer (LC/MS Ion Trap 1100
series) was set to ESI in positive ion mode. Additional settings of the mass spectrometer
were as follows: Scan mode (standard), range (50-2200) m/z, speed (13,000 m/z/min),
threshold (1000), nebulizer gas (15.0 psi), and dry gas (5.0 L/min), dry temp (325 °C).
The target mass was set to 282 while the compound stability and trap drive level were set
to 100%. The ramp range was from 4500.0 to 1500.0 V. The ms/ms fragmentation amp
was set to 1.00 V.
Results and Discussion
Bulk electrolysis/cyclic voltammetry analysis. Bulk electrolysis and cyclic
voltammetry analysis of artemisinin were performed using the same setup and conditions
except the working electrodes were different. The objective of bulk electrolysis was to
reduce a 0.03M solution of artemisinin in quantitative amounts with the purpose to
characterize and identify the reduction products. Aliquots of the reaction mixture were
withdrawn every hour then filtered and analyzed using chromatographic and mass
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spectrometry techniques. Cyclic voltammograms for the artemisinin solution were
recorded at 30 minutes intervals during electrolysis. The cyclic voltammograms at 0, 30,
and 60 minutes are shown in Figure 22.
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Figure 22. Cyclic voltammograms of Art and electrolyzed Art solutions. The CVs were
taken after 30 min and 60 min of electrolysis using a gold working electrode at 1.5 V
potential.

The voltammograms taken at 30, and 60 minutes show electrochemical reduction
of Art as compared to the voltammogram of Art before electrolysis. The broadening of
existing peaks and formation of new peaks is evidence of reduction product formation.
Mugweru et al. 74 performed a detailed study of the electron transfer characteristics of
artemisinin on three different types electrode, a gold (Au), glassy carbon (GC), and
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pyrolytic graphite (PG) working electrodes. The gold electrode was determined to have
greater sensitivity towards the reduction of Art. Therefore, the kinetic parameters for the
electrochemical reaction were obtained using a gold working electrode. According to
Mugweru et al. 74, the reduction of Art on gold electrode surface is diffusion controlled
and follows an EC mechanism. The kinetic parameters obtained on this study are reported
here (Table 2).

Table 2
Electrochemical parameters for reduction of artemisinin on gold (Au), glassy carbon
(GC), and pyrolytic graphite (PG) working electrodes.
Type of
working
electrode

Average
current density
(μAcm−2)
at 100mVs–1

Diffusion
coefﬁcient
(D) (cms−1)

Electron
transfer
coefﬁcient
(αn)

Number of
electrons
transferred
(n)

Gold (Au)

4.62

3.34 × 10−6

0.496

1.52  2

GC, PG

1.28, 1.53

--

--

--

Rate
constant
(kh)

23 cm
s−1
--

HPLC-MS analysis. The chromatograms in Figure 23 suggest reduction of Art
and product formation as a function of electrolysis time. The retention time of the drug
before reduction was determined to be at 25.8 minutes (Figure 23a). After one hour to
three hours of electrolysis, the development of new peaks due to the formation of
reduction products is clear as figures 23b and 23c show. To identify the products formed
by the electrolysis of artemisinin, the solutions were analyzed by mass spectrometry.
Figure 24a shows the mass spectrum of Art before reduction. The molecular ion can be
identified with a mass of 282.8, m+1 (283.8), m+2 (284.8) and m + sodium (m+23)
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(304.8). The mass spectra of electrolyzed Art solutions show masses of possible
reduction products. Reduction of Art at the C=O bond produces dihydroartemisinin and
the loss of oxygen from the peroxide bridge produces deoxy artemisinin (Figure 24b).
According to the mass spectra, it can be deduced that these two products were formed
although further analysis is needed to confirm this result.
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Figure 23. Chromatograms of artemisinin: a) before electrolysis; b) before and after 1 hr.
of electrolysis; c) after 2 and 3 hours of electrolysis.
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b)

Figure 24. Mass spectrometry of artemisinin: a) before electrolysis showing m/z
corresponding to artemisinin and; b) after 3 hrs. of electrolysis showing m/z for possible
reduction products deoxy artemisinin and dihydroartemisinin.
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Conclusion
Electrochemical reduction of artemisinin was performed during this work. Bulk
electrolysis of Art, for a three hours period at a fixed reductive potential (1.5 V versus
Ag/ AgCl), yielded reduction products as the HPLC analysis showed. The cyclic
voltammograms taken at 30 minutes intervals during electrolysis corroborate these
findings. Dihydroartemisinin and deoxy artemisinin are thought to be among the products
formed. Reduction of Art on gold electrode surface follows and EC mechanism. The
electron process is irreversible and limited by diffusion controlled mass transport as
reported by 74.
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Chapter 5
Hemoglobin Catalyzed Bioactivation of Artemisinin
Introduction
The action of artemisinin against malaria parasites is thought to be hememediated, although as of now the detailed mechanism has not been reported 75.
Understanding the precise mode of action of artemisinin will allow the design of more
potent analogs for malaria and cancer treatments, and aid in deciphering the resistance
mechanism from the malaria parasite. plasmodium falciparum goes through several
stages of development within the host’s red blood cells. Throughout its development, the
parasite ingests and degrades most of the hemoglobin in host’s cells. Due to this process,
the parasite digestive vacuole is rich in iron provided by the heme prosthetic group of
hemoglobin 76. Artemisinin is highly selective towards plasmodium falciparum-infected
red blood cells. This observation can be used to rationalize the iron-dependent bioactivation of the endoperoxide group of artemisinin 75. Currently, there are two proposed
pathways for artemisinin bio-activation the reductive cleavage model and the open
peroxide model. The reductive cleavage model proposes that artemisinin bio-activation is
triggered by the reduction of the endoperoxide bond by Fe (II) to generate oxygen
radicals. The highly reactive oxygen radicals rearrange to generate carbon-centered
radicals. Primary and secondary carbon-centered radicals have been detected after iron
activation using electro-paramagnetic resonance spin-trapping techniques. Proponents of
the open peroxide model argue that carbon radicals cannot exist long enough to have any
intramolecular interactions. Instead, they propose that artemisinin acts as a source of
hydrogen peroxide which undergoes a Fenton like reaction to produced hydroxyl radicals
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capable of irreversibly damaging proteins and other macromolecules. In this model, iron
behaves like a Lewis acid and facilitates the cleavage of the endoperoxide bond. The nonperoxidic oxygen is believed to provide stabilization to lower the amount of energy
required to break the oxygen bridge 75.
The principal molecular target of artemisinin is yet to be identified. The fact that
artemisinin can produce different reactive intermediates including carbon and hydroxyl
radicals indicates that it can interact with a wide range of macromolecules. Various
research groups have reported the identification of heme-artemisinin adducts by mass
spectrometry 76. These findings suggest that inhibition of globin formation and
accumulation of heme within the malaria parasite and cancer cells can cause parasite
death and cancer cells apoptosis. Other proposed molecular targets of plasmodium
falciparum are proteins, cell membranes, and mitochondria. Oxidative stress has been
reported as a cause of cancer cell apoptosis. The mechanism of action of artemisinin
within cancer cells is believed to be similar the mechanism that causes death to malaria
parasites. On the other hand, some studies have identified DNA damage caused by
artemisinin that is independent of oxidative stress. In this research, the reductive mode of
artemisinin bio-activation was investigated using a carbon nanofibers/hemoglobin-based
electrochemical biosensor.
Experimental Methods
Chemicals. Artemisinin was purchased from Tokyo Chemical Industry CO. LTD.
Acetonitrile, methanol was purchased from VWR. PSS, Carbon nanofibers and
hemoglobin (Hb, MW 66,000) were purchased from Sigma Chemical Co. The nanofibers
had a diameter 100 nm diameter and a variable length between 20-200 μm. They were
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used without further purification. A concentrated (0.004 M) ART solution was made in
20 mM acetate buffer pH 5.5 containing 1% methanol. The solution was used as a stock
solution for all other experiments. Hemoglobin was used without any additional
purification. All other chemicals were HPLC grade.
Electrochemical procedures. Cyclic voltammetry and amperometric analysis
were carried out with a computer controlled electrochemical workstation (CHI 660c,
USA) with 98% ohmic drop (IR) compensation. A three-electrode electrochemical cell
was used for all electrochemical experiments. A glassy carbon electrode (0.07 cm2) and a
pyrolytic carbon electrode were used as working electrode while a platinum wire as
counter electrode. The Ag/AgCl reference electrode was equipped with a glass tip
separated from the sample solution compartment by a salt-bridge containing saturated
KCl and terminating in a medium porosity glass frit. Before use, glassy carbon electrodes
were polished using 1 µm diamond polishing paste then ultra-sonicated in ethanol and
distilled water successively for 1 min followed by rinsing with water. All electrochemical
measurements were carried out under ambient conditions.
Hemoglobin/PSS biosensor preparation. A pyrolytic Carbon working electrode
was used to prepare the biosensor. A thin slice of the electrode was cut off to expose a
pristine electrode surface before the assembly. 2µL of a 45mg/ml of hemoglobin solution
in acetate buffer (pH 5.5) was set on the pyrolytic carbon electrode surface and then left
to dry at room temperature. A second layer consisting of 2µL of PSS solution in DI water
was set on the hemoglobin modified electrode and allowed to dry at room temperature.
The electrode was rinsed with DI water to removes any unattached material. The
electrochemical cell contained 10 ml of 20 mM acetate buffer pH 5.5 as the supporting
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electrolyte solution. To avoid oxygen interference, the electrolyte solution was purged
with nitrogen gas (N2) for five minutes to remove the oxygen before the analysis.
Hemoglobin/CNFs biosensor preparation. The biosensor was assembled using
a glassy carbon (GC) electrode. The GC electrode surface was modified using carbon
nanofibers (CNFs). 2 µL of a 2mg/ml suspension of CNFs in DMS was carefully placed
on the surface of a previously cleaned GC electrode and allowed to dry at room
temperature. A second layer consisting of 2µL of a 45mg/ml of hemoglobin solution in
acetate buffer (pH 5.5) was set on the CNFs modified electrode and allowed to dry at
room temperature. The electrochemical cell contained 10 ml of 20 mM acetate buffer pH
5.5 as the supporting electrolyte solution. To avoid oxygen interference, the electrolyte
solution was purged with nitrogen gas (N2) for five minutes to remove the oxygen prior
to the analysis.
Results and Discussion
Hemoglobin/polystyrene sulphonate (PSS) biosensor. Hemoglobin is an
oxygen-transporting protein found in red blood cells. It includes four heme prosthetic
groups each containing an iron molecule in the center. Due to the presence of Iron (II),
the heme groups are electroactive which makes hemoglobin an ideal recognition
molecule for assembling electrochemical biosensors. Immobilization of hemoglobin on
the electrode surface is a critical step since the immobilization procedure may alter its
normal behavior. Hemoglobin’s conformation must be kept intact for it to remain active
after immobilization. There are many different methods for immobilizing enzymes onto
the electrode. One of the simplest methods is to entrap the enzyme between the electrode
and a dialysis membrane or a polymeric film. This biosensor was prepared by entrapping
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a hemoglobin solution between the surface of a pyrolytic carbon electrode and a film of
polystyrene sulfonate. Several layers of hemoglobin and PSS were assembled to improve
the results. The voltammogram taken before purging with nitrogen showed a well define
reduction peak due to the presence of oxygen in solution. After purging the solution with
nitrogen gas, the cyclic voltammetric results did not show well-defined reduction and
oxidation peaks. Well-defined redox peaks are expected after purging. Otherwise, the
biosensor may not be assembled correctly. These results could indicate that good contact
between hemoglobin and the sensing material was not achieved or that the enzyme was
denatured during the assembly. A different method using carbon nanofibers to
immobilize hemoglobin was utilized to continue the experiment.
Carbon nanofibers (CNFs)/ hemoglobin biosensor. Carbon nanomaterials such
as carbon nanotubes, graphite powder, and carbon nanofibers are ideal materials for
construction of biosensors due to their excellent conductivity, large surface area, and
biocompatibility. According to Vamvakaki et al. 77, carbon nanofibers are superior to
carbon nanotubes or graphite powder for direct immobilization of enzymes onto their
surface since CNFs have larger functionalized surface area. Also, CNFs’ high porosity
and absorption ability support enzyme immobilization 78. Therefore, CNFs were preferred
to assemble this biosensor. A layer consisting of 2 µL of a 2mg/ml suspension of CNFs in
DMS was placed on the polished glassy carbon electrode’s surface and allowed to dry.
Subsequently, a layer of the hemoglobin solution was placed on the CNFs modified
electrode and allowed to dry before analyzing it. Figure 2 shows a schematic of the
biosensor assembly.
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Figure 25. Schematic representation for assembly of GC/CNFs/Hb biosensor.

The biosensor was tested prior to the study of artemisinin by evaluating
hemoglobin bioactivity using cyclic voltammetry. After purging the solution with
nitrogen to drive out the oxygen, reduction and oxidation peaks are observed due to the
redox reaction of iron in hemoglobin. During the forward scan iron (II) is oxidized to iron
(III) while during the reverse scan iron (III) is reduced and becomes iron (II) again.
Consistent results after purging the solution confirm the reliability of the biosensor and
the favorable conformation and bioactivity of hemoglobin. Artemisinin was added to the
electrochemical cell containing 10 ml of acetate buffer. 0.2 ml of artemisinin solution
was added incrementally to obtain greater concentration after each addition. The solution
was analyzed after each Art addition using cyclic voltammetry. Figure 26 shows the
cyclic voltammogram of some selected concentrations of artemisinin. As clearly
illustrated in the figure, the voltammogram at 0.0 µM of artemisinin is completely
reversible. This is due to the iron in hemoglobin been oxidized and subsequently reduced
at the electrode surface. After addition of 0.8 µM of artemisinin, the oxidation peak is
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noticeably decreased, and the reduction peak increases. This trend continues as the
concentration of artemisinin is increased. At 5.8 µM, the oxidation peak is mostly gone.

Figure 26. Cyclic voltammograms obtained from reduction of Art using Hb/CNFs
biosensor, at (0.0 µM, 0.8 µM, 1.2 µM, 2.6 µM, 5.8 µM) of artemisinin.

In this case, artemisinin is being reduced by iron (II) which is consequently
oxidized to iron (III). The results indicate that hemoglobin catalyzes artemisinin’s
peroxide bridge reduction and subsequent radical formation is possible. Studies have
shown that after reduction of artemisinin, oxygen and carbon-centered radicals are
formed 79. These very reactive radical species are thought to be responsible for the
eradication of the malaria parasite and cancer cells.
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Hemoglobin-catalyzed reduction of artemisinin. Reduction of artemisinin on
glassy carbon electrode surface was investigated by Mugweru et al. 74. The peak potential
was found to be - 0.85 V versus Ag/AgCl reference electrode. In this work, peak potential
of hemoglobin anchored onto carbon nanofibers is about -0.30 V vs. Ag/AgCl. The
reduction potential of artemisinin on CNFs/Hb modified glassy carbon electrode averages
at about – 0.375 V vs. Ag/AgCl. The results show the electrocatalytic effect of
hemoglobin towards the reduction of artemisinin. The reduction potential of artemisinin
was catalytically reduced by about 475 mV. Hemoglobin anchored on CNFs must be
properly oriented such that the heme prosthetic group can interact with artemisinin during
the electrochemical analysis. The catalytic activity of hemoglobin toward artemisinin
correlates closely with the orientation of the heme groups in Hb 78. A line Weaver-Burke
plot (Figure 27) was obtained using the peak current produced with increasing
concentration of artemisinin. The Michaelis–Menten constant (Km) for Art reduction on
CNF/Hb modified glassy carbon electrode was determined using the Weaver-Burke plot
and equations 6 and 7.
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Figure 27. Line Weaver-Burk plot using GC/CNFs/Hb voltammograms.
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Equation 7

Where Km represents the Michaelis-Menten constant, which indicates the enzymesubstrate kinetics. Iss is the steady-state current obtained from GC /CNF/Hb CV
measurements. Imax is the maximum current obtained from CVs at saturated Art solutions.
The apparent Km for this system was found to be 0.093 mM according to the kinetic
studies. Table 3 compares the Km for hemoglobin from several literature articles and this
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study based on the surface the enzyme is immobilized as well as the substrate under
study. The Km value for hemoglobin in solution is about three times smaller than that
found in this study which makes sense given that the enzyme was not immobilized.
Therefore, it was free to interact with the substrate.

Table 3
Michaelis-Menten constant (Km) of hemoglobin immobilized on different materials’
surfaces.
Materials

Substrates

Km (mM)

References

Iron nanoparticles

Hydrogen peroxide

0.29

80

mesoporous silica

Hydrogen peroxide

2.87

81

in solution

Artemisinin

0.028

Carbon nanofibers

Artemisinin

0.093

82

This study

Effect of artemisinin concentration. Figure 26 shows cyclic voltammograms of
GC/CNF/Hb modified electrode obtained at increasing concentration of Art. The peak
current increases as the concentration of Art is increased. The catalytic peak current
increases linearly with Art concentrations between 0 and 200 μM (Figure 28). This linear
relationship was used to estimate the sensitivity of GC/CNF/Hb modified electrode for
Art catalysis. The linear relationship showed the slope as 0.329 mA/mM with a
regression coefficient of (R = 0.99436).
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Figure 28. Current versus concentration of artemisinin obtained from cyclic
voltammograms.

Effect of scan rate. The cyclic voltammogram of CNFs/Hb modified glassy
carbon electrode at 100 mV/s exhibits well-defined redox peaks at −0.22 V and −0.38 V
vs. Ag/AgCl (Figure 29). The formal potential (E0’) was −0.30 V vs. Ag/AgCl. CVs
were also taken at scan rates of 100 mV/s and 200 mV/s in the presence of 0.20 mM ART
solution (Figure 30). At 200 mV/s, the CV exhibits both the oxidation and reduction
peaks as in CVs taken in the absence of artemisinin while at 100 mV/s, the oxidation
peak is gone. This indicates that at scan rates 100 mV/s and lower Art reacts with
HbFe(II) rendering the system irreversible. The magnitude of the scan rate affects the
system in that at higher scan rates, electron transfer between iron and the electrode is fast
enough so that the chemical step does not occur. Therefore, a reversible behavior is
observed.
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Figure 29. Cyclic voltammogram of CNFs/Hb modified GC electrode. CV taken in 20
mM acetate buffer pH 5.5 at 100 mV/s-1.

Figure 30. Cyclic voltammograms of GC/CNFs/Hb taken at 100 and 200 mV/s-1 scan
rates. The CVs were carried out in 20 mM acetate buffer pH 5.5 containing 0.2 mM Art.
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Amperometric analysis of CNFs/Hb biosensor. The CNFs/hemoglobin
biosensor was analyzed further using Amperometry to confirm its reliability and
corroborate the results obtained by cyclic voltammetry. For this experiment, the
electrochemical cell was set up similar to that for cyclic voltammetry. Addition of
constant amounts of artemisinin to the electrochemical cell, containing 10 ml of the
electrolyte solution, was done at 200 seconds intervals to allow the resulting current to
equilibrate. The resulting current due to the reduction of artemisinin increased as the
concentration of artemisinin in solution was increased. These results suggest that the
biosensor worked as expected and that reductive bioactivation of artemisinin by HbFe(II)
occurred on the electrode surface.
Conclusion
A sensitive carbon nanofiber/hemoglobin biosensor was assembled which was
able to detect catalytic bioactivation of artemisinin by heme-bound iron (Fe II) using
cyclic voltammetry. The GC/CNF/Hb system was also able to detect increased Art
concentration in solution. The catalytic current generated upon subsequent additions of
0.2 ml Art solution was proportional to the concentration of Art in the electrochemical
cell. This result shows that the assembled GC/CNF/Hb biosensor can be used for the
determination of unknown concentration of analytes. From the cyclic voltammograms
obtained, it can be inferred that hemoglobin was strongly anchored onto the CNFs’
surface. Well defined cathodic and anodic peaks were observed for the GC/CNF/Hb
system in the absence of artemisinin. In the presence of artemisinin, a well-defined
cathodic peak is observed. This implies that the conformation of hemoglobin in this
system was very favorable. The Michaelis-Menten constant (Km) of hemoglobin towards
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Art reduction was 0.093 mM. From literature, other similar systems with hemoglobin
immobilized on different materials generated higher Km values.
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